Wolters Kluwer Launches AI-enhanced UpToDate Enterprise Edition in EMEA
Revolutionizing Clinical Decision Support for healthcare systems with AI for search, usage analytics, and more
Wolters Kluwer Health today announced its UpToDate® Enterprise Edition will be available to healthcare systems and hospitals in the Europe, Middle East, and Africa (EMEA) region beginning in Q3. Designed specifically for large healthcare systems and hospitals, the clinical decision support (CDS) solution, which features AI enhancements, is designed to support healthcare administrators and clinicians to help deliver consistently high-quality care. Wolters Kluwer Health will demonstrate the solution at HIMSS25 Europe in Paris, June 10-12, 2025.
“Leveraging AI technology, UpToDate Enterprise Edition goes beyond traditional decision support to provide unparalleled quality that supports streamlined, integrated workflows and faster time-to-answers, ultimately fostering patient engagement and transforming care delivery,” said Christian Cella, Vice President, International Segment for Clinical Effectiveness at Wolters Kluwer Health. “With UpToDate Enterprise becoming available in EMEA, we are extending Wolters Kluwer’s commitment to enhancing clinical decision-making worldwide.”
For decades, healthcare professionals around the world have trusted UpToDate clinical decision support to enable confident decision-making and reduce variability in care. The UpToDate Enterprise Edition solution builds on that value to include advanced features, insights, and technology innovations to help them meet these current and emerging industry challenges. The solution is in early release at 40 of the largest health systems in EMEA joining the over 350 health systems in North America using the UpToDate Enterprise Edition.
“UpToDate has been an extremely valuable clinical decision support resource for Icelandic health institutions. UpToDate Enterprise Edition adds new features including AI that will aid our staff to make smarter clinical decisions to further help improve patient care,” says Runólfur Pálsson, CEO of Landspítali University Hospital and Professor of Medicine at the Faculty of Medicine of the University of Iceland.
UpToDate Enterprise Edition offers harmonized content and solutions for the entire care team, empowering them to make more informed, confident, and impactful decisions. With its AI-Enhanced Search capabilities, clinicians can now experience the efficiency of receiving highly focused verbatim answers from a market leading clinical decision solution using natural language queries—a time-saver for busy healthcare professionals. The AI-powered Analytics Dashboard offers healthcare organizations the ability to harness valuable organizational data for improved efficiency and educational opportunities.
“Deploying UpToDate Enterprise Edition is an important initiative in supporting our digital innovation strategy,” said Professor Adrian Harris, Chief Medical Officer at the Royal Devon University Healthcare NHS Foundation Trust. “By leveraging the data, analytics and AI capabilities now available within UpToDate, we can further support medical education and optimize clinical decision making, helping us deliver the best possible care for all patients and enabling our local population to stay well.”
This enhanced solution unifies care teams and administrators with a focus on workflow innovation, analytics, and advanced care features. With access across teams, organizations can:
- Manage complexity by advancing clinical decisions
- Enhance satisfaction and collaboration by aligning all members of the care team to the same trusted UpToDate content with advanced decision-making features
- Help alleviate burnout through improved workflow capabilities
- Improve resource utilization and business outcomes via system-wide data and insights and self-service analytics, such as system-wide topic usage, UpToDate topic benchmarking, and CME accreditation activity.
In the Frost Radar™: Clinical Decision Support System, 2025report, Wolters Kluwer was the only one named both a “Company to Action” and the market leader for innovation. Frost & Sullivan screened and analyzed more than 60 clinical decision support vendors across point-of-care segments and short-listed 10 companies based on a detailed analysis of their corporate growth potential and ability to drive visionary innovation in this space.
Learn more about UpToDate Enterprise Edition in EMEA.
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.
Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Facebook, YouTube and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250604785080/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 18:00:00 CEST | Press release
- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conferenc
Andersen Consulting tilføjer dimension med David and Golyat6.6.2025 16:33:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin globale konsulentkapacitet gennem en samarbejdsaftale med David and Golyat, en filippinsk konsulentvirksomhed inden for digital strategi. Med et stærkt fokus på business intelligence, kundeindsigt og digital first-eksekvering arbejder David and Golyat med kunder på tværs af flere sektorer – herunder regeringer, udviklingsorganisationer og private virksomheder – for at skabe langsigtet værdi gennem datainformerede beslutninger. Miko David, administrerende partner i David and Golyat, siger: "Vi ser frem til samarbejdet med Andersen Consulting, da det er en milepæl i vores vækstforløb. Ved at kombinere vores ekspertise inden for digital strategi og Andersen Consultings globale platform er vi i stand til at levere endnu større værdi til kunder, der navigerer på komplekse markeder." "Dette samarbejde betyder, at vi kan tilføre en ekstra dimension til vores globale konsulentplatform," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktø
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology6.6.2025 16:00:00 CEST | Press release
IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine.With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty.This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 14:00:00 CEST | Press release
Pivotal Study Advances to Establish Histotripsy as a Non-Thermal, Surgery-Free Alternative to Destroy and Liquefy Kidney Tumors HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison
Norwegian Tech Firm Builds Military Command Center in 24 Hours6.6.2025 13:45:00 CEST | Press release
Norwegian technology provider Cyviz has successfully developed a fully mobile and ballistic-proof command center - designed, configured, and made operational in just 24 hours. The solution was showcased during a military exercise led by the Dutch Ministry of Defence and has already sparked interest from NATO members and civil protection agencies across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606640770/en/ Cyviz demonstrates rapid deployment capability with a mobile, container-based control room for defense and crisis response Cyviz and its partners constructed the command room inside a 14-ton container designed for transport on standard military vehicles and resistant to machine gun fire. The unit was deployed at a military base in the Netherlands, where Cyviz was tasked with delivering a fully functional command-and-control environment, under strict time constraints and in a high-stakes simulation. "You do
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom